吉西他滨和顺铂新辅助化疗联合手术治疗非小细胞肺癌的临床观察

Efficacy Evaluation of GP Neoadjuvant Chemotherapy Combined with Surgery in the Treatment of Non-small Cell Lung Cancer

目的探讨吉西他滨和顺铂(GP)新辅助化疗联合手术治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效及对免疫功能和肿瘤标志物的影响。方法收集NSCLC 100例,根据治疗方式不同分成对照组、观察组,均50例。对照组手术治疗,观察组在对照组的基础上增加吉西他滨和顺铂新辅助化疗。统计2组临床疗效。结果观察组临床有效率(94.00%)高于对照组(χ^(2)=14.918,P<0.001)。治疗前,2组CEA、CA19-9、CA125水平比较,P>0.05;治疗后,2组CEA、CA19-9、CA125水平均下降,组间比较,观察组CEA、CA19-9、CA125水平低于对照组(P<0.05)。治疗前,2组T淋巴细胞亚群水平比较,P>0.05;治疗后,2组T淋巴细胞亚群水平均下降,组间比较,观察组T淋巴细胞亚群水平高于对照组(P<0.05)。观察组不良反应发生率(4.00%)低于对照组(χ^(2)=6.061,P=0.014)。治疗前,2组格拉斯哥昏迷评分比较,P>0.05;治疗2周后、6月后,2组格拉斯哥昏迷评分均上升,组间比较,2组格拉斯哥昏迷评分比较,P<0.05。结论吉西他滨和顺铂新辅助化疗联合手术治疗非小细胞肺癌,可降低患者肿瘤标志物水平,提高临床疗效,对机体免疫功能损伤小,安全性高,值得推广。

Objective To investigate the clinical efficacy of gemcitabine and cisplatin(GP)neoadjuvant chemotherapy combined with surgery in the treatment of non-small cell lung cancer(NSCLC)and the effects on immune function and tumor markers.Methods 100 cases of NSCLC were collected and divided into the control group and the observation group(50 cases in all)according to different treatment methods.The control group was treated with surgery,and the observation group was additionally treated with gemcitabine and cisplatin neoadjuvant chemotherapy.The clinical effect of 2 groups was analyzed.Results The clinical effective rate of the observation group(94.00%)was higher than that of the control group(χ^(2)=14.918,P<0.001).Before treatment,the levels of CEA,CA19-9 and CA125 in the 2 groups were compared,P>0.05;After treatment,CEA,CA19-9 and CA125 levels in the 2 groups were decreased,CEA,CA19-9 and CA125 levels in the observation group were lower than those in the control group(P<0.05).Before treatment,the level of T lymphocyte subsets in 2 groups were compared,P>0.05;After treatment,the level of T lymphocyte subsets in both groups decreased,and the level of T lymphocyte subsets in the observation group was higher than that in the control group(P<0.05).The incidence of adverse reactions in the observation group(4.00%)was lower than that in the control group(χ^(2)=6.061,P=0.014).Before treatment,the Glasgow coma score of 2 groups was compared,P>0.05;After 2 weeks and 6 months of treatment,the Glasgow coma score increased in both groups.Compared between groups,the Glasgow coma score between the 2 groups was compared,P<0.05.Conclusion Gemcitabine and cisplatin neoadjuvant chemotherapy combined with surgery in the treatment of patients with non-small cell lung cancer can reduce the level of tumor markers in patients,improve clinical efficacy,reduce immune function damage,high safety,worthy of promotion.